Pharmaceutical Technology on MSN3d
FDA expands Novartis’ Kisqali label to include early breast cancer patientsKisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...
Previously, Ms. Shaw was an executive at Novartis Pharmaceutical Corporation, including as U.S. country head and President of Novartis Pharmaceutical Corporation and as North American region head ...
Previously, Ms. Shaw was an executive at Novartis Pharmaceutical Corporation, including as U.S. country head and President of Novartis Pharmaceutical Corporation and as North American region head of ...
HARDING TWP. - Now on display at the Kemmerer Library art gallery are the works of Nancy J. Ori, the featured artist for ...
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...
Judge Andrews of the District of Delaware recently denied Novartis’s request for a preliminary injunction against MSN Pharmaceuticals. Novartis Pharm. Corp. v. MSN Pharm. Inc., Civil Action No ...
Kajeet and Avery Telehealth announced a strategic partnership. The FDA has approved Apple’s sleep apnea detection feature.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback